<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04782076</url>
  </required_header>
  <id_info>
    <org_study_id>17972</org_study_id>
    <secondary_id>J2G-MC-JZJV</secondary_id>
    <nct_id>NCT04782076</nct_id>
  </id_info>
  <brief_title>A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants</brief_title>
  <official_title>An Open-Label Study to Investigate the Effect of Selpercatinib on the Pharmacokinetics of Dabigatran in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loxo Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine the effect of selpercatinib on the levels of&#xD;
      dabigatran in the blood stream and how long it takes the body to remove dabigatran. This&#xD;
      study will also look at how safe and well-tolerated of dabigatran when administered in&#xD;
      combination with selpercatinib in healthy participants. This study will last approximately 22&#xD;
      to 25 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 5, 2021</start_date>
  <completion_date type="Actual">May 17, 2021</completion_date>
  <primary_completion_date type="Actual">May 17, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of Dabigatran</measure>
    <time_frame>Predose up to 72 hours post-dose on Days 1 and 8</time_frame>
    <description>PK: Cmax of Dabigatran</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-inf]) of Dabigatran</measure>
    <time_frame>Predose up to 72 hours post-dose on Days 1 and 8</time_frame>
    <description>PK: AUC(0-inf) of Dabigatran</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK: Cmax of Selpercatinib</measure>
    <time_frame>Predose up to 72 hours post-dose on Day 8</time_frame>
    <description>PK: Cmax of Selpercatinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC(0-inf) of Selpercatinib</measure>
    <time_frame>Predose up to 72 hours post-dose on Day 8</time_frame>
    <description>PK: AUC(0-inf) of Selpercatinib</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dabigatran + Selpercatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dabigatran as single dose administered orally on Day 1 followed by a single dose of dabigatran coadministered with a single dose of selpercatinib on Day 8 orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Dabigatran + Selpercatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selpercatinib</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Dabigatran + Selpercatinib</arm_group_label>
    <other_name>LY3527723</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Overtly healthy males or females, as determined by medical history, physical&#xD;
             examination and vital signs.&#xD;
&#xD;
          -  Body mass index (BMI) within the range of 19 to 35 kilograms per meter squared (kg/m²)&#xD;
&#xD;
          -  Male participants are not required to adhere to contraceptive requirements and female&#xD;
             participants of childbearing potential must agree to be either remain abstinent or&#xD;
             stay in a same sex relationship without sexual relationships with males or must agree&#xD;
             to use a highly effective method of contraception and who underwent bilateral&#xD;
             salpingectomy. The Female participants not of childbearing potential are not required&#xD;
             to use contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a positive pregnancy test at screening or Day -1, where applicable&#xD;
&#xD;
          -  Are planning to become pregnant during the study or within 1 month of study completion&#xD;
&#xD;
          -  Are women who are lactating&#xD;
&#xD;
          -  Have known allergies to selpercatinib- or dabigatran-related compounds or any&#xD;
             components of the formulation of selpercatinib or dabigatran, or history of&#xD;
             significant atopy&#xD;
&#xD;
          -  Have a history of allergic reactions to medications or food products&#xD;
&#xD;
          -  Have a clinically significant abnormality of blood pressure and/or pulse rate as&#xD;
             determined by the investigator&#xD;
&#xD;
          -  Have known bleeding disorder including prior personal or familiar history of abnormal&#xD;
             bleeding, hereditary or acquired coagulation or platelet disorder&#xD;
&#xD;
          -  Clinically significant abnormalities on ECG as determined by the investigator or&#xD;
             prolongation of the QTcB or QTcF &gt;450 msec on more than 1 ECG obtained during&#xD;
             screening only&#xD;
&#xD;
          -  Have clinically significant active cardiovascular disease or history of myocardial&#xD;
             infarction within 6 months prior to the planned start of selpercatinib&#xD;
&#xD;
          -  Are currently enrolled in any other clinical study involving an investigational&#xD;
             product or any other type of medical research judged not to be scientifically or&#xD;
             medically compatible with this study&#xD;
&#xD;
          -  Have an average weekly alcohol intake that exceeds 21 units per week (males ≤65 years&#xD;
             old) and 14 units per week (females); 1 unit = 12 oz or 360 mL of beer; 5 oz or 150 mL&#xD;
             of wine; 1.5 oz or 45 mL of distilled spirit(s)&#xD;
&#xD;
          -  Are smokers of more than 10 cigarettes or e-cigarettes, or 3 cigars or 3 pipes, per&#xD;
             day&#xD;
&#xD;
          -  Consume excessive amounts of coffee, tea, cola, or other caffeinated beverages per day&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Inc</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

